Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myeloma
•
Hematology
Do you recommend autologous transplant in patients with AL-amyloidosis who have a complete hematologic response to daratumumab-CyBorD?
Related Questions
What is your approach to MRD testing in the frontline treatment of multiple myeloma?
How do you discuss harms of MGUS screening with other medical providers?
How do you approach post-transplant maintenance for patients with high-risk myeloma?
How do you utilize immunoglobulin testing to affect treatment decisions in patients with myeloma?
How would you approach choosing a regimen for a patient with multiple myeloma refractory to daratumumab and lenalidomide, with severe neuropathy from bortezomib?
How would you approach the treatment of an elderly patient with multiple myeloma and CALR+ myelofibrosis with elevated platelets?
How is monoclonal gammopathy of renal significance (MGRS) different from myeloma kidney?
Is a bone marrow biopsy necessary in a patient with a previous tissue diagnosis of plasmacytoma or smoldering multiple myeloma, who now meets criteria for active myeloma?
What post-auto maintenance therapy do you recommend for patients with high-risk multiple myeloma?
What induction regimen do you choose for high risk newly diagnosed multiple myeloma in light of the recent high risk focused studies?
